ANTIBODY MICROARRAY FOR DETECTION OF TUMOR MARKERS

描述(申请人提供)：稳定抗体的发展 同时检测和定量检测多个肿瘤的微阵列 提出了血液、尿液和组织中的标志物。这些阵列将增加 肿瘤标志物在肿瘤诊断、疗效评价中的诊断价值 和分子图谱的基础研究，通过允许同时 与相同类型的标记物相关的多组标记的测量 癌症。关键的创新是使用了电化学生长的基质 (氧化Ir)固定抗体并保持其活性，其 应用成熟的微电极阵列制作方法 生产稳定的蛋白质微阵列。所有的组件都可以很容易地 微型化到电路板级别，功率要求非常适中。这个 阵列的设计使得它们可以同时进行电化学 来自单个小体积样本的多分析免疫分析(SMAI)。在第一阶段 我们将演示两个肿瘤的同时检测和量化 前列腺特异性抗原(PSA)和癌胚抗原(CEA) 使用SMAI为我们的抗体提供概念验证验证 微阵列系统。 建议的商业应用： 抗体阵列将用于从体液中检测和量化多个肿瘤市场 癌组织和培养细胞的提取物。癌症标志物的潜在用途包括 在普通人群中进行筛查，癌症的临床分期，估计肿瘤体积， 监测治疗反应，检测癌症复发和基础研究 癌症的分子图谱。

DESCRIPTION (provided by applicant): The development of stable antibody microarrays for the simultaneous detection and quantification of multiple tumor markers in blood, urine and tissue is proposed. The arrays will increase the diagnostic value of tumor markers in cancer diagnosis, assessment of treatment, and basic research in molecular profiling, by allowing the simultaneous measurement of multiple groups of markers associated with the same types of cancer. The key innovation is the use of an electrochemically grown matrix (iridium oxide) to immobilize antibodies and maintain their activity, and its application with well-established microelectrode array fabrication methods to produce stable protein microarrays. All the components can be readily miniaturized to circuit board level with very modest power requirements. The design of the arrays is such that they can perform electrochemical simultaneous multianalyte immunoassays (SMAI) from single, small volume samples. In Phase I we will demonstrate the simultaneous detection and quantification of two tumor markers, prostate-specific antigen (PSA) and carcinoembryonic antigen (CEA) using SMAI in order to provide proof-of-concept validation of our antibody microarray system. PROPOSED COMMERCIAL APPLICATION: Antibody arrays will be used to detect and quantify multiple tumor markets from body fluids or extracts of cancer tissues and cultured cells. Potential uses of cancer markers include screening in the general population, clinical staging of cancer, estimating tumor volume, monitoring response to therapy, detecting the recurrence of cancer and basic research in the molecular profiling of cancer.